Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models.

Tumor vascularity is correlated with an aggressive disease phenotype in neuroblastoma, suggesting that angiogenesis inhibitors may be a useful addition to current therapeutic strategies. We previously showed that the antiangiogenic compound TNP-470, an irreversible methionine aminopeptidase 2 (MetAP2) inhibitor, suppressed local and disseminated human neuroblastoma growth rates in murine models but had significant associated toxicity at the effective dose. We have recently shown that a novel, reversible MetAP2 inhibitor, A-357300, significantly inhibits CHP-134-derived neuroblastoma s.c. xenograft growth rate with a treatment-to-control (T/C) ratio at day 24 of 0.19 (P < 0.001) without toxicity. We now show that the combination of A-357300 with cyclophosphamide at the maximal tolerated dose sustained tumor regression with a T/C at day 48 of 0.16 (P < 0.001) in the CHP-134 xenograft model. A-357300 also significantly inhibited establishment and growth rate of hematogenous metastatic deposits following tail vein inoculation of CHP-134 cells and increased overall survival (P = 0.021). Lastly, A-357300 caused regression of established tumors in a genetically engineered murine model with progression-free survival in five of eight mice (P < 0.0001). There was no evidence of toxicity. These data show that MetAP2 may be an important molecular target for high-risk human neuroblastomas. We speculate that the growth inhibition may be through both tumor cell intrinsic and extrinsic (antiangiogenic) mechanisms. The potential for a wide therapeutic index may allow for treatment strategies that integrate MetAP2 inhibition with conventional cytotoxic compounds.
AuthorsMichael J Morowitz, Rosalind Barr, Qun Wang, Rebecca King, Nicholas Rhodin, Bruce Pawel, Huaqing Zhao, Scott A Erickson, George S Sheppard, Jieyi Wang, John M Maris, Suzanne Shusterman
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 11 Issue 7 Pg. 2680-5 (Apr 1 2005) ISSN: 1078-0432 [Print] United States
PMID15814649 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • A357300
  • Antineoplastic Agents, Alkylating
  • Chlorobenzenes
  • MYCN protein, human
  • Nuclear Proteins
  • Oncogene Proteins
  • Cyclophosphamide
  • Aminopeptidases
  • methionine aminopeptidase 2
  • Metalloendopeptidases
  • Aminopeptidases (antagonists & inhibitors)
  • Animals
  • Antineoplastic Agents, Alkylating (therapeutic use)
  • Chlorobenzenes (pharmacology, therapeutic use)
  • Cyclophosphamide (therapeutic use)
  • Drug Therapy, Combination
  • Humans
  • Metalloendopeptidases (antagonists & inhibitors)
  • Mice
  • Mice, Inbred Strains
  • Mice, Nude
  • Mice, SCID
  • Mice, Transgenic
  • Neuroblastoma (pathology, prevention & control)
  • Nuclear Proteins (genetics, metabolism)
  • Oncogene Proteins (genetics, metabolism)
  • Survival Analysis
  • Treatment Outcome
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: